Parvalbumin-positive GABAergic interneurons deficit in the hippocampus in Gunn rats: A possible hyperbilirubinemia-induced animal model of schizophrenia.

Anatomy Biochemistry Cell biology Developmental biology GABA Gunn rat Hyperbilirubinemia Immunology Molecular biology Neuroscience Parvalbumin Schizophrenia

Journal

Heliyon
ISSN: 2405-8440
Titre abrégé: Heliyon
Pays: England
ID NLM: 101672560

Informations de publication

Date de publication:
Jul 2019
Historique:
received: 28 09 2018
revised: 18 05 2019
accepted: 01 07 2019
entrez: 20 7 2019
pubmed: 20 7 2019
medline: 20 7 2019
Statut: epublish

Résumé

A reduction of GABAergic markers in postmortem tissue is consistently found in schizophrenia. Importantly, these alterations in GABAergic neurons are not global, which means they are more prevalent among distinct subclasses of interneurons, including those that express the calcium binding protein parvalbumin. A decreased expression of parvalbumin in the hippocampus is a consistent observation not only in postmortem human schizophrenia patients, but also in a diverse number of rodent models of the disease. Meanwhile, previously we reported that the congenital hyperbilirubinemia model rats (Gunn rats), which is a mutant of the Wistar strain, showed behavioral abnormalities, for instance, hyperlocomotor activity, deficits of prepulse inhibition, inappropriate social interaction, impaired recognition memory similar with several rodent models of schizophrenia. Several animal studies linked the importance of palvalbumin in relation to abnormal hippocampal activity and schizophrenia-like behavior. Here, we show that parvalbumin positive cell density was significantly lower in the CA1, CA3 and the total hippocampus of Gunn rats (congenital hyperbilirubinemia model rats) compared to Wistar control rats. The correlations between serum UCB levels and loss of PV expression in the hippocampus were also detected. The decreases in the PV-expression in the hippocampus might suggest an association of the behavioral abnormalities as schizophrenia-like behaviors of Gunn rats, compared to the Wistar control rats.

Identifiants

pubmed: 31321330
doi: 10.1016/j.heliyon.2019.e02037
pii: S2405-8440(19)35697-X
pii: e02037
pmc: PMC6612903
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e02037

Références

J Neuroinflammation. 2016 Sep 02;13(1):230
pubmed: 27590010
Transl Psychiatry. 2015 Mar 10;5:e522
pubmed: 25756805
Neuroscience. 2007 Dec 12;150(3):625-38
pubmed: 17981403
Neuron. 2010 Jan 14;65(1):7-19
pubmed: 20152109
Nat Rev Neurosci. 2016 Feb;17(2):125-34
pubmed: 26763624
Int J Neuropsychopharmacol. 2009 Sep;12(8):1097-110
pubmed: 19267957
J Neural Transm (Vienna). 2007 Jul;114(7):893-8
pubmed: 17594127
Science. 2007 Dec 7;318(5856):1645-7
pubmed: 18063801
Psychiatry Res. 2011 Oct 30;189(3):480-2
pubmed: 21470692
Brain Behav. 2018 Aug;8(8):e01028
pubmed: 29953737
Prog Neuropsychopharmacol Biol Psychiatry. 2009 Jun 15;33(4):581-8
pubmed: 19249333
Nat Rev Neurosci. 2005 Apr;6(4):312-24
pubmed: 15803162
J Neurosci. 2009 Feb 25;29(8):2344-54
pubmed: 19244511
Handb Exp Pharmacol. 2012;(213):267-95
pubmed: 23027419
J Neurosci. 2003 Jul 16;23(15):6315-26
pubmed: 12867516
Neuropharmacology. 2012 Mar;62(3):1574-83
pubmed: 21277876
Synapse. 2009 Mar;63(3):186-92
pubmed: 19086090
J Neuroinflammation. 2012 Mar 16;9:56
pubmed: 22424389
Science. 2002 Apr 26;296(5568):692-5
pubmed: 11976442
Biol Psychiatry. 2011 Jan 15;69(2):113-26
pubmed: 20678756
J Psychopharmacol. 2007 Mar;21(2):198-205
pubmed: 17329300
Neuropsychopharmacology. 2012 Jan;37(1):4-15
pubmed: 21956446
Front Psychol. 2015 Nov 26;6:1805
pubmed: 26635701
Curr Pharm Des. 2009;15(25):2915-26
pubmed: 19754368
Schizophr Res. 2011 Sep;131(1-3):165-73
pubmed: 21745723
Neurosci Lett. 2011 Jan 25;488(3):267-71
pubmed: 21094213
J Clin Psychiatry. 2000 Nov;61(11):868-71
pubmed: 11105741
Can Med Assoc J. 1944 Mar;50(3):230-7
pubmed: 20323028
PLoS Med. 2005 May;2(5):e141
pubmed: 15916472
J Neuroinflammation. 2015 Sep 29;12:182
pubmed: 26416717
Prog Neuropsychopharmacol Biol Psychiatry. 2014 Apr 3;50:184-90
pubmed: 24389395
Pediatr Neurol. 2003 Nov;29(5):410-21
pubmed: 14684236
Prog Neurobiol. 2003 Jul;70(4):319-45
pubmed: 12963091
Transl Psychiatry. 2012 Feb 21;2:e81
pubmed: 22832818
Asian J Psychiatr. 2013 Apr;6(2):119-23
pubmed: 23466107
J Pediatr. 1969 Dec;75(6):1070-9
pubmed: 5389393
Brain Res. 2004 Nov 5;1026(1):33-43
pubmed: 15476695
J Neuroinflammation. 2013 Dec 05;10:145
pubmed: 24305622
Mol Pharmacol. 2002 Aug;62(2):257-64
pubmed: 12130676
Behav Brain Res. 2009 Dec 7;204(2):352-62
pubmed: 19433116
Psychopharmacology (Berl). 2000 Jun;150(2):163-9
pubmed: 10907669
Free Radic Biol Med. 2002 Nov 1;33(9):1186-93
pubmed: 12398926
Acta Neuropathol. 2006 Jul;112(1):95-105
pubmed: 16733655

Auteurs

Maiko Hayashida (M)

Department of Psychiatry, Faculty of Medicine, Shimane University, Japan.

Tsuyoshi Miyaoka (T)

Department of Psychiatry, Faculty of Medicine, Shimane University, Japan.

Keiko Tsuchie (K)

Department of Psychiatry, Faculty of Medicine, Shimane University, Japan.

Tomoko Araki (T)

Department of Psychiatry, Faculty of Medicine, Shimane University, Japan.

Muneto Izuhara (M)

Department of Psychiatry, Faculty of Medicine, Shimane University, Japan.

Shoko Miura (S)

Department of Psychiatry, Faculty of Medicine, Shimane University, Japan.

Misako Kanayama (M)

Department of Psychiatry, Faculty of Medicine, Shimane University, Japan.

Koji Ohtsuki (K)

Department of Psychiatry, Faculty of Medicine, Shimane University, Japan.

Michiharu Nagahama (M)

Department of Psychiatry, Faculty of Medicine, Shimane University, Japan.

Ilhamuddin Abdul Azis (IA)

Department of Psychiatry, Faculty of Medicine, Shimane University, Japan.

Rostia Arianna Abdullah (RA)

Department of Psychiatry, Faculty of Medicine, Shimane University, Japan.

Muhammad Alim Jaya (MA)

Department of Psychiatry, Faculty of Medicine, Shimane University, Japan.

Ryosuke Arauchi (R)

Department of Psychiatry, Faculty of Medicine, Shimane University, Japan.

Sadayuki Hashioka (S)

Department of Psychiatry, Faculty of Medicine, Shimane University, Japan.

Rei Wake (R)

Department of Psychiatry, Faculty of Medicine, Shimane University, Japan.

Toshiko Tsumori (T)

Department of Nursing, Faculty of Health and Welfare, Prefectural University of Hiroshima, Japan.

Jun Horiguchi (J)

Division of Immune-Neuropsychiatry, Faculty of Medicine, Shimane University, Japan.

Arata Oh-Nishi (A)

Division of Immune-Neuropsychiatry, Faculty of Medicine, Shimane University, Japan.
RESVO Inc., Japan.

Masatoshi Inagaki (M)

Department of Psychiatry, Faculty of Medicine, Shimane University, Japan.

Classifications MeSH